Can Denosumab cure giant cell tumors of the spine? A case report and literature review
- 70 Downloads
Bone giant cell tumors, although benign, may be locally aggressive and cause severe morbidity; in some cases, they can also disseminate at distance and cause death. Denosumab has been approved to treat unresectable bone giant cell tumors or when surgery is likely to result in severe morbidity. Furthermore, its curative potential has been recently suggested.
An 18-year-old girl presented with a spinal giant cell tumor at T9. Neo-adjuvant denosumab was administered for 9 months with great clinical and analytical tolerance. A posterior left T9 costo-transversectomy and vertebral body curettage was performed and the spine stabilized. Interestingly, histopathology examination of the surgical specimens found no evidence of tumoral cells. Denosumab was reinstated until completion of 12 months of treatment.
Denosumab has an important but still limited role in the treatment of spinal giant cell tumors. Here, it resulted in complete histological resolution of the tumor, potentially widening its applicability from a strictly neo-adjuvant to a curative role.
KeywordsGiant cell tumor GCT Spine Denosumab
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest in relation to this article.
- 1.Heck R Jr, Toy P (2017) Benign/aggressive tumors of bone. In: Azar FMM, Beaty JH, Canale ST (eds) Campbell’s operative orthopaedics, 13th edn. Elsevier, Philadelphia, pp 923–944.e3Google Scholar